[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Salmeterol.]
[J01EC02, sulfadiazine, The metabolism of Sulfadiazine can be decreased when combined with Salmeterol.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Sulfamethoxazole.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Sulindac is combined with Salmeterol.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Sulpiride.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Salmeterol is combined with Azapropazone.]
[L01BB02, mercaptopurine, The risk or severity of hypokalemia can be increased when Mercaptopurine is combined with Salmeterol.]
[N06DA01, tacrine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Salmeterol.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Salmeterol.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Salmeterol.]
[R03CC03, terbutaline, The risk or severity of adverse effects can be increased when Terbutaline is combined with Salmeterol.]
[G03BA03, testosterone, The metabolism of Salmeterol can be decreased when combined with Testosterone.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Tetrabenazine.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Lurasidone.]
[A04AD10, dronabinol, The risk or severity of Tachycardia can be increased when Dronabinol is combined with Salmeterol.]
[N04BC07, apomorphine, The metabolism of Apomorphine can be decreased when combined with Salmeterol.]
[L04AX02, thalidomide, The metabolism of Salmeterol can be increased when combined with Thalidomide.]
[R03DA07, theobromine, The risk or severity of hypokalemia can be increased when Theobromine is combined with Salmeterol.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Salmeterol.]
[A11DA01, thiamine, The risk or severity of adverse effects can be increased when Salmeterol is combined with Thiamine.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Eribulin.]
[N05AB08, thioproperazine, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Thioproperazine.]
[N05AC02, thioridazine, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Thiothixene.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Salmeterol is combined with Moxisylyte.]
[S01ED01, timolol, Timolol may decrease the bronchodilatory activities of Salmeterol.]
[M02AX02, tolazoline, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Tolazoline.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be decreased when combined with Salmeterol.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Tolmetin is combined with Salmeterol.]
[N02AX02, tramadol, The risk or severity of Tachycardia can be increased when Tramadol is combined with Salmeterol.]
[N06AF04, tranylcypromine, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Salmeterol.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Salmeterol.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Salmeterol.]
[S01BA05, triamcinolone, The risk or severity of hypokalemia can be increased when Triamcinolone is combined with Salmeterol.]
[N05CD05, triazolam, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triazolam is combined with Salmeterol.]
[C03AA06, trichlormethiazide, The risk or severity of hypokalemia can be increased when Salmeterol is combined with Trichlormethiazide.]
[A03AB12, mepenzolate, The risk or severity of Tachycardia can be increased when Salmeterol is combined with Mepenzolate.]
[N05AB06, trifluoperazine, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Trifluoperazine.]
[N05AA05, triflupromazine, The risk or severity of Tachycardia can be increased when Triflupromazine is combined with Salmeterol.]
[D07AC02, fluclorolone, The risk or severity of hypokalemia can be increased when Fluclorolone is combined with Salmeterol.]
[N04AA01, trihexyphenidyl, The risk or severity of Tachycardia can be increased when Trihexyphenidyl is combined with Salmeterol.]
[R03BA07, mometasone, The risk or severity of hypokalemia can be increased when Mometasone is combined with Salmeterol.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Alimemazine.]
[N03AC02, trimethadione, The metabolism of Trimethadione can be decreased when combined with Salmeterol.]
[C02BA01, trimethaphan, Salmeterol may decrease the antihypertensive activities of Trimethaphan.]
[J01EA01, trimethoprim, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Salmeterol.]
[N06AA06, trimipramine, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Trimipramine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Salmeterol.]
[A03BB01, butylscopolamine, The risk or severity of Tachycardia can be increased when Salmeterol is combined with Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Salmeterol can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The risk or severity of hypertension can be increased when Salmeterol is combined with Vilazodone.]
[C09CA09, azilsartan medoxomil, Salmeterol may decrease the antihypertensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Salmeterol is combined with Tubocurarine.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Vandetanib.]
[A10BH05, linagliptin, The metabolism of Salmeterol can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Salmeterol can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Salmeterol can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ezogabine.]
[B01AF01, rivaroxaban, The metabolism of Rivaroxaban can be decreased when combined with Salmeterol.]
[R03AC18, indacaterol, The risk or severity of adverse effects can be increased when Salmeterol is combined with Indacaterol.]
[B01AC24, ticagrelor, The metabolism of Ticagrelor can be decreased when combined with Salmeterol.]
[C08DA01, verapamil, The metabolism of Verapamil can be decreased when combined with Salmeterol.]
[N06AX09, viloxazine, The metabolism of Salmeterol can be decreased when combined with Viloxazine.]
[C04AX07, vincamine, Salmeterol may decrease the antihypertensive activities of Vincamine.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Salmeterol.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Salmeterol is combined with Xenon.]
[C03BA10, xipamide, Salmeterol may decrease the antihypertensive activities of Xipamide.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be decreased when combined with Salmeterol.]
[N05AF05, zuclopenthixol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Salmeterol can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Salmeterol.]
[M05BA03, pamidronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Salmeterol.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be decreased when combined with Salmeterol.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Salmeterol.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ziprasidone.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Salmeterol is combined with Acetylsalicylic acid.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Tolterodine.]
[C07AB03, atenolol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Atenolol.]
[J02AC03, voriconazole, The metabolism of Salmeterol can be decreased when combined with Voriconazole.]
[S01FA01, atropine, The risk or severity of hypertension can be increased when Atropine is combined with Salmeterol.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Salmeterol.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be decreased when combined with Salmeterol.]
[H02AB11, prednylidene, The risk or severity of hypokalemia can be increased when Prednylidene is combined with Salmeterol.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Salmeterol.]
[M03BX01, baclofen, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Salmeterol.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Salmeterol can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Salmeterol can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Enzalutamide can be increased when it is combined with Salmeterol.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Salmeterol is combined with Octopamine.]
[H02AA01, aldosterone, The risk or severity of hypokalemia can be increased when Aldosterone is combined with Salmeterol.]
[J05AE04, nelfinavir, The metabolism of Salmeterol can be decreased when combined with Nelfinavir.]
[N04BD02, rasagiline, The risk or severity of hypertension can be increased when Salmeterol is combined with Rasagiline.]
[C08CA13, lercanidipine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Salmeterol.]
[N03AX22, perampanel, The metabolism of Perampanel can be decreased when combined with Salmeterol.]
[N02CC03, zolmitriptan, The risk or severity of hypertension can be increased when Zolmitriptan is combined with Salmeterol.]
[R06AC06, thonzylamine, The risk or severity of Tachycardia can be increased when Salmeterol is combined with Thonzylamine.]
[G04BD10, darifenacin, The risk or severity of Tachycardia can be increased when Darifenacin is combined with Salmeterol.]
[N01AA01, ethyl ether, The risk or severity of hypertension can be increased when Salmeterol is combined with Diethyl ether.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Pasireotide.]
[G04BE03, sildenafil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Salmeterol.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Salmeterol.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Salmeterol.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Bencyclane.]
[C03AA01, bendroflumethiazide, The risk or severity of hypokalemia can be increased when Salmeterol is combined with Bendroflumethiazide.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Salmeterol is combined with Benorilate.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Moxifloxacin.]
[M01AH01, celecoxib, The metabolism of Celecoxib can be decreased when combined with Salmeterol.]
[N02CC02, naratriptan, The risk or severity of hypertension can be increased when Salmeterol is combined with Naratriptan.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Salmeterol.]
[L01EC02, dabrafenib, The serum concentration of Dabrafenib can be increased when it is combined with Salmeterol.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Salmeterol is combined with Benzydamine.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Salmeterol.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be decreased when combined with Salmeterol.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Bepridil.]
[C02KX05, riociguat, The metabolism of Riociguat can be decreased when combined with Salmeterol.]
[C02KX04, macitentan, Salmeterol may decrease the antihypertensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Salmeterol.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Salmeterol.]
[J05AP05, simeprevir, The metabolism of Salmeterol can be decreased when combined with Simeprevir.]
[C01CA27, droxidopa, The risk or severity of adverse effects can be increased when Salmeterol is combined with Droxidopa.]
[C07AB04, acebutolol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Acebutolol.]
[A16AA07, metreleptin, The metabolism of Salmeterol can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Salmeterol can be increased when combined with Apremilast.]
[N07CA01, betahistine, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Betahistine.]
[S03BA03, betamethasone, The risk or severity of hypokalemia can be increased when Betamethasone is combined with Salmeterol.]
[S01ED02, betaxolol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Betaxolol.]
[C02CC01, bethanidine, Salmeterol may decrease the antihypertensive activities of Bethanidine.]
[C10AB02, bezafibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Bezafibrate.]
[L04AC11, siltuximab, The metabolism of Salmeterol can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ceritinib.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Salmeterol.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Salmeterol.]
[D11AA01, glycopyrronium, The risk or severity of Tachycardia can be increased when Salmeterol is combined with Glycopyrronium.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Eliglustat.]
[N05AA04, acepromazine, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Acepromazine.]
[V04CX03, methacholine, Salmeterol may decrease effectiveness of Methacholine as a diagnostic agent.]
[N04AA02, biperiden, The risk or severity of Tachycardia can be increased when Biperiden is combined with Salmeterol.]
[S03AA06, gentamicin, The serum concentration of Gentamicin can be increased when it is combined with Salmeterol.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Salmeterol.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Salmeterol.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Salmeterol.]
[L04AC10, secukinumab, The metabolism of Salmeterol can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Palbociclib is combined with Salmeterol.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Panobinostat.]
[J05AP07, daclatasvir, The metabolism of Daclatasvir can be decreased when combined with Salmeterol.]
[A03AA09, difemerine, The risk or severity of Tachycardia can be increased when Salmeterol is combined with Difemerine.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ivabradine.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Salmeterol.]
[N05AX16, brexpiprazole, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of hypertension can be increased when Salmeterol is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of hypertension can be increased when Salmeterol is combined with Cariprazine.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Salmeterol is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Salmeterol is combined with Acemetacin.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Acipimox.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Salmeterol.]
[L01CX01, trabectedin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Trabectedin.]
[J02AC05, isavuconazole, The metabolism of Salmeterol can be decreased when combined with Isavuconazole.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Salmeterol.]
[G04CA01, alfuzosin, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Alfuzosin.]
[J05AP10, elbasvir, The metabolism of Elbasvir can be decreased when combined with Salmeterol.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Salmeterol is combined with Alminoprofen.]
[L01XX52, venetoclax, The metabolism of Salmeterol can be decreased when combined with Venetoclax.]
[N04BC01, bromocriptine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Salmeterol.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Salmeterol.]
[N06AA19, amineptin, The risk or severity of hypertension can be increased when Amineptine is combined with Salmeterol.]
[C08CA01, amlodipine, Salmeterol may decrease the antihypertensive activities of Amlodipine.]
[C03CA02, bumetanide, The risk or severity of hypokalemia can be increased when Salmeterol is combined with Bumetanide.]
[C07AA19, bupranolol, Bupranolol may decrease the bronchodilatory activities of Salmeterol.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be decreased when combined with Salmeterol.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Buserelin.]
[N05BE01, buspirone, The risk or severity of hypertension can be increased when Buspirone is combined with Salmeterol.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Artemether.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Salmeterol.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Salmeterol.]
[L01XK03, rucaparib, The metabolism of Salmeterol can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Azithromycin.]
[L01EF02, ribociclib, The metabolism of Salmeterol can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Salmeterol is combined with Balsalazide.]
[R03CC12, bambuterol, The risk or severity of adverse effects can be increased when Salmeterol is combined with Bambuterol.]
[R03DA08, bamifylline, The risk or severity of hypokalemia can be increased when Bamifylline is combined with Salmeterol.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Salmeterol.]
[N06BC01, caffeine, The risk or severity of hypokalemia can be increased when Caffeine is combined with Salmeterol.]
[C09AA07, benazepril, Salmeterol may decrease the antihypertensive activities of Benazepril.]
[J01XX08, linezolid, The risk or severity of hypertension can be increased when Linezolid is combined with Salmeterol.]
[J05AE09, tipranavir, The metabolism of Salmeterol can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Salmeterol.]
[L04AB02, infliximab, The metabolism of Salmeterol can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Salmeterol can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Salmeterol.]
[N04BD03, safinamide, The risk or severity of hypertension can be increased when Salmeterol is combined with Safinamide.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Delafloxacin.]
[S01EB09, acetylcholine, The risk or severity of adverse effects can be increased when Salmeterol is combined with Acetylcholine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Salmeterol.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Vorinostat.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Salmeterol.]
[C07AB07, bisoprolol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Bisoprolol.]
[R03AC17, bitolterol, The risk or severity of adverse effects can be increased when Bitolterol is combined with Salmeterol.]
[J05AG03, efavirenz, The metabolism of Salmeterol can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, Bopindolol may decrease the bronchodilatory activities of Salmeterol.]
[N04AA11, bornaprine, The risk or severity of Tachycardia can be increased when Salmeterol is combined with Bornaprine.]
[R03BA02, budesonide, The risk or severity of hypokalemia can be increased when Budesonide is combined with Salmeterol.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Salmeterol is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Salmeterol is combined with Bumadizone.]
[L01EL02, acalabrutinib, The metabolism of Salmeterol can be decreased when combined with Acalabrutinib.]
[J05AX18, letermovir, The metabolism of Salmeterol can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of hypertension can be increased when Butriptyline is combined with Salmeterol.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Acetyldigoxin.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Acrivastine.]
[C09AA01, captopril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Captopril.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Macimorelin.]
[L02BB05, apalutamide, The serum concentration of Apalutamide can be increased when it is combined with Salmeterol.]
[N03AF01, carbamazepine, The metabolism of Carbamazepine can be decreased when combined with Salmeterol.]
[A03AA03, camylofine, The risk or severity of Tachycardia can be increased when Salmeterol is combined with Camylofin.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Salmeterol.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Carbinoxamine.]
[C07AG02, carvedilol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Carvedilol.]
[N03AX24, cannabidiol, The metabolism of Salmeterol can be decreased when combined with Cannabidiol.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Encorafenib.]
[C07AB08, celiprolol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Salmeterol.]
[L01XX62, ivosidenib, The metabolism of Salmeterol can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Salmeterol can be decreased when combined with Stiripentol.]
[J05AG06, doravirine, The metabolism of Doravirine can be decreased when combined with Salmeterol.]
[L01EB07, dacomitinib, The risk or severity of adverse effects can be increased when Dacomitinib is combined with Salmeterol.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Salmeterol.]
[R06AA06, chlorphenoxamine, The risk or severity of Tachycardia can be increased when Salmeterol is combined with Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Salmeterol is combined with Lornoxicam.]
[R03DA02, oxtriphylline, The risk or severity of hypokalemia can be increased when Oxtriphylline is combined with Salmeterol.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Inotersen.]
[L01ED05, lorlatinib, The metabolism of Lorlatinib can be decreased when combined with Salmeterol.]
[L04AA39, emapalumab, The metabolism of Salmeterol can be increased when combined with Emapalumab.]
[L01EX13, gilteritinib, The risk or severity of adverse effects can be increased when Gilteritinib is combined with Salmeterol.]
[L01XJ03, glasdegib, The metabolism of Glasdegib can be decreased when combined with Salmeterol.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Amifampridine.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Cibenzoline.]
[C09AA08, cilazapril, Salmeterol may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Cilostazol.]
[A03FA08, cinitapride, The risk or severity of hypertension can be increased when Salmeterol is combined with Cinitapride.]
[C10AB08, ciprofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Ciprofibrate.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Salmeterol.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Salmeterol is combined with Siponimod.]
[J01FA09, clarithromycin, The metabolism of Salmeterol can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Salmeterol.]
[H02AB14, cloprednol, The risk or severity of hypokalemia can be increased when Cloprednol is combined with Salmeterol.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Ubidecarenone.]
[C09CA06, candesartan, Salmeterol may decrease the antihypertensive activities of Candesartan.]
[L04AB01, etanercept, The metabolism of Salmeterol can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The risk or severity of hypokalemia can be increased when Cortivazol is combined with Salmeterol.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Cicletanine.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Salmeterol can be decreased when it is combined with Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Salmeterol.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Salmeterol.]
[C03AA09, cyclothiazide, The risk or severity of hypokalemia can be increased when Salmeterol is combined with Cyclothiazide.]
[G04BE04, yohimbine, The risk or severity of hypertension can be increased when Salmeterol is combined with Yohimbine.]
[J01XX09, daptomycin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Salmeterol.]
[H02AB13, deflazacort, The risk or severity of hypokalemia can be increased when Deflazacort is combined with Salmeterol.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Salmeterol.]
[N03AX25, cenobamate, The serum concentration of Salmeterol can be decreased when it is combined with Cenobamate.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Salmeterol.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Dexchlorpheniramine.]
[N05CM21, lemborexant, The metabolism of Lemborexant can be decreased when combined with Salmeterol.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Salmeterol can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Salmeterol can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of hypertension can be increased when Salmeterol is combined with Frovatriptan.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Salmeterol is combined with Dutasteride.]
[L04AA38, ozanimod, The metabolism of Ozanimod can be decreased when combined with Salmeterol.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Salmeterol.]
[N02CC06, eletriptan, The risk or severity of hypertension can be increased when Eletriptan is combined with Salmeterol.]
[M01AH02, rofecoxib, The risk or severity of hypertension can be increased when Rofecoxib is combined with Salmeterol.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be decreased when combined with Salmeterol.]
[S03AA08, chloramphenicol, The metabolism of Salmeterol can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Chlorcyclizine.]
[C02AA06, methoserpidine, Salmeterol may decrease the antihypertensive activities of Methoserpidine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Salmeterol.]
[A03AA08, dihexyverine, The risk or severity of Tachycardia can be increased when Salmeterol is combined with Dihexyverine.]
[C01CA14, dopexamine, The risk or severity of hypertension can be increased when Salmeterol is combined with Dopexamine.]
[D07XB03, fluprednidene, The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Salmeterol.]
[G04BD09, trospium, The risk or severity of Tachycardia can be increased when Trospium is combined with Salmeterol.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Salmeterol is combined with Droxicam.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Salmeterol is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Salmeterol is combined with Dexketoprofen.]
[C08CA17, levamlodipine, Salmeterol may decrease the antihypertensive activities of Levamlodipine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Fostemsavir.]
[L04AC19, satralizumab, The serum concentration of Salmeterol can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, The metabolism of Chloroquine can be decreased when combined with Salmeterol.]
[L01EX23, pralsetinib, The metabolism of Salmeterol can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The risk or severity of hypokalemia can be increased when Salmeterol is combined with Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Salmeterol.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Chlorpromazine.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Chlorprothixene.]
[C03BA04, chlorthalidone, Salmeterol may decrease the antihypertensive activities of Chlorthalidone.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Salmeterol is combined with Ethenzamide.]
[N02BA03, choline salicylate, The serum concentration of Choline salicylate can be increased when it is combined with Salmeterol.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Etodolac is combined with Salmeterol.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Salmeterol is combined with Etofenamate.]
[C10AB09, etofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Etofibrate.]
[B06AC06, berotralstat, The metabolism of Salmeterol can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Salmeterol can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Relugolix.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Salmeterol is combined with Naxitamab.]
[P03AX07, abametapir, The serum concentration of Salmeterol can be increased when it is combined with Abametapir.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Felbamate.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Salmeterol is combined with Fenbufen.]
[N06BA10, fenethylline, The risk or severity of hypokalemia can be increased when Fenethylline is combined with Salmeterol.]
[C01CA19, fenoldopam, Salmeterol may decrease the antihypertensive activities of Fenoldopam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Salmeterol is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Salmeterol is combined with Finasteride.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Flumequine.]
[R03BA03, flunisolide, The risk or severity of hypokalemia can be increased when Flunisolide is combined with Salmeterol.]
[R03CC15, formoterol, Salmeterol may increase the sympathomimetic activities of Formoterol.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Salmeterol.]
[N01AB05, trichloroethylene, The risk or severity of hypertension can be increased when Salmeterol is combined with Trichloroethylene.]
[H04AA02, dasiglucagon, Salmeterol may decrease the antihypertensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Salmeterol.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Salmeterol can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Salmeterol can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The risk or severity of hypokalemia can be increased when Cisplatin is combined with Salmeterol.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Citalopram.]
[C03DA05, finerenone, The metabolism of Finerenone can be decreased when combined with Salmeterol.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Salmeterol is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Clemastine.]
[R03CC13, clenbuterol, The risk or severity of adverse effects can be increased when Salmeterol is combined with Clenbuterol.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be decreased when combined with Salmeterol.]
[N06AX25, St. John's wort extract, The metabolism of Salmeterol can be increased when combined with St. John's Wort.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Salmeterol.]
[C10AB01, clofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Clofibrate is combined with Salmeterol.]
[L01EJ03, pacritinib, The serum concentration of Salmeterol can be increased when it is combined with Pacritinib.]
[N06AA04, clomipramine, The risk or severity of hypertension can be increased when Clomipramine is combined with Salmeterol.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Salmeterol.]
[C01EB24, mavacamten, The serum concentration of Salmeterol can be decreased when it is combined with Mavacamten.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be decreased when combined with Salmeterol.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Granisetron.]
[N05AH02, clozapine, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Clozapine.]
[H01AC08, somatrogon, The metabolism of Salmeterol can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Cocaine.]
[C02KB01, metyrosine, Salmeterol may decrease the antihypertensive activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Salmeterol can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Salmeterol is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Salmeterol.]
[M04AC01, colchicine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Colchicine.]
[A03AB10, hexocyclium, The risk or severity of Tachycardia can be increased when Salmeterol is combined with Hexocyclium.]
[A03BB06, homatropine methylbromide, The risk or severity of Tachycardia can be increased when Homatropine methylbromide is combined with Salmeterol.]
[L04AA13, leflunomide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Desflurane.]
[C04AX28, ifenprodil, The risk or severity of hypertension can be increased when Salmeterol is combined with Ifenprodil.]
[A10BX03, nateglinide, The metabolism of Salmeterol can be decreased when combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Salmeterol is combined with Imidazole salicylate.]
[J01FA15, telithromycin, The metabolism of Salmeterol can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of hypokalemia can be increased when Ciclesonide is combined with Salmeterol.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Salmeterol is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Desloratadine.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Valdecoxib is combined with Salmeterol.]
[A03AX10, isometheptene, The risk or severity of hypertension can be increased when Salmeterol is combined with Isometheptene.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Salmeterol.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Salmeterol is combined with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Salmeterol can be decreased when combined with Itraconazole.]
[S01AD03, acyclovir, The risk or severity of adverse effects can be increased when Acyclovir is combined with Salmeterol.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Emedastine.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Salmeterol is combined with Kebuzone.]
[L01EA01, imatinib, The metabolism of Imatinib can be decreased when combined with Salmeterol.]
[J02AC04, posaconazole, The metabolism of Salmeterol can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Lacidipine.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Salmeterol.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Levocabastine.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Salmeterol.]
[S01BA03, cortisone, The risk or severity of hypokalemia can be increased when Cortisone is combined with Salmeterol.]
[N07BC04, lofexidine, Salmeterol may decrease the antihypertensive activities of Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Salmeterol is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Salmeterol is combined with Loxoprofen.]
[C09AA03, lisinopril, Salmeterol may decrease the antihypertensive activities of Lisinopril.]
[C08CA11, manidipine, Salmeterol may decrease the antihypertensive activities of Manidipine.]
[A03AA04, mebeverine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Mebeverine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Salmeterol is combined with Mefenorex.]
[C07AA14, mepindolol, Mepindolol may decrease the bronchodilatory activities of Salmeterol.]
[H02AB15, meprednisone, The risk or severity of hypokalemia can be increased when Meprednisone is combined with Salmeterol.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Mequitazine.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Adenosine.]
[N04AA03, methixene, The risk or severity of Tachycardia can be increased when Metixene is combined with Salmeterol.]
[R03CB02, methoxyphenamine, The risk or severity of hypertension can be increased when Salmeterol is combined with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Cyclizine.]
[C03DA04, eplerenone, Salmeterol may decrease the antihypertensive activities of Eplerenone.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Melperone.]
[C03AA07, cyclopenthiazide, The risk or severity of hypokalemia can be increased when Salmeterol is combined with Cyclopenthiazide.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Salmeterol.]
[N06AX07, minaprine, The risk or severity of hypertension can be increased when Minaprine is combined with Salmeterol.]
[S01XA18, cyclosporine, The metabolism of Cyclosporine can be decreased when combined with Salmeterol.]
[N06AG02, moclobemide, The risk or severity of hypertension can be increased when Salmeterol is combined with Moclobemide.]
[N06BA07, modafinil, The metabolism of Salmeterol can be increased when combined with Modafinil.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Salmeterol.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Salmeterol.]
[C10AA07, rosuvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Rosuvastatin.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Salmeterol is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Salmeterol is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Salmeterol can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, Salmeterol may decrease the antihypertensive activities of Moxonidine.]
[L01BC01, cytarabine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Cytarabine.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Salmeterol.]
[M01AH05, etoricoxib, The risk or severity of hypertension can be increased when Salmeterol is combined with Etoricoxib.]
[G03XA01, danazol, The metabolism of Salmeterol can be decreased when combined with Danazol.]
[J04BA02, dapsone, The metabolism of Dapsone can be decreased when combined with Salmeterol.]
[L01DB02, daunorubicin, The metabolism of Salmeterol can be increased when combined with Daunorubicin.]
[C02CC04, debrisoquin, Salmeterol may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of Tachycardia can be increased when Nabilone is combined with Salmeterol.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Nabumetone is combined with Salmeterol.]
[C07AB12, nebivolol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Nebivolol.]
[N06AX06, nefazodone, The metabolism of Salmeterol can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Salmeterol may decrease the antihypertensive activities of Nicorandil.]
[C01CA23, theodrenaline, The risk or severity of hypertension can be increased when Salmeterol is combined with Theodrenaline.]
[C01CA05, norfenefrine, The risk or severity of hypertension can be increased when Salmeterol is combined with Norfenefrine.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Salmeterol is combined with Olsalazine.]
[N06AA01, desipramine, The risk or severity of hypertension can be increased when Desipramine is combined with Salmeterol.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Salmeterol.]
[D07XC02, desoximetasone, The risk or severity of hypokalemia can be increased when Desoximetasone is combined with Salmeterol.]
[H02AA03, desoxycorticosterone, The risk or severity of hypokalemia can be increased when Desoxycortone is combined with Salmeterol.]
[C09XA02, aliskiren, Salmeterol may decrease the antihypertensive activities of Aliskiren.]
[L01XA03, oxaliplatin, The serum concentration of Oxaliplatin can be increased when it is combined with Salmeterol.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Salmeterol is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The metabolism of Salmeterol can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Salmeterol can be increased when combined with Dexamethasone.]
[N04AA08, dexetimide, The risk or severity of Tachycardia can be increased when Salmeterol is combined with Dexetimide.]
[G04BD04, oxybutynin, The metabolism of Oxybutynin can be decreased when combined with Salmeterol.]
[A03AA01, oxyphencyclimine, The risk or severity of Tachycardia can be increased when Oxyphencyclimine is combined with Salmeterol.]
[L04AB04, adalimumab, The metabolism of Salmeterol can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Salmeterol can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Salmeterol.]
[R05DA09, dextromethorphan, The metabolism of Salmeterol can be decreased when combined with Dextromethorphan.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be decreased when combined with Salmeterol.]
[N06AB05, paroxetine, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Salmeterol.]
[B01AC04, clopidogrel, The risk or severity of adverse effects can be increased when Clopidogrel is combined with Salmeterol.]
[C04AD01, pentifylline, The risk or severity of hypokalemia can be increased when Pentifylline is combined with Salmeterol.]
[N05BA01, diazepam, The metabolism of Salmeterol can be decreased when combined with Diazepam.]
[V03AH01, diazoxide, Salmeterol may decrease the antihypertensive activities of Diazoxide.]
[N06AA08, dibenzepin, The risk or severity of hypertension can be increased when Dibenzepin is combined with Salmeterol.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be decreased when combined with Salmeterol.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Salmeterol.]
[A03AA07, dicyclomine, The risk or severity of Tachycardia can be increased when Dicyclomine is combined with Salmeterol.]
[C02DG01, pinacidil, Salmeterol may decrease the antihypertensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Pinaverium.]
[A10BG03, pioglitazone, The serum concentration of Pioglitazone can be increased when it is combined with Salmeterol.]
[A03AB14, pipenzolate, The risk or severity of Tachycardia can be increased when Salmeterol is combined with Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Salmeterol.]
[R03CC07, pirbuterol, The risk or severity of adverse effects can be increased when Salmeterol is combined with Pirbuterol.]
[C03CA03, piretanide, The risk or severity of hypokalemia can be increased when Salmeterol is combined with Piretanide.]
[A08AA03, diethylpropion, The risk or severity of hypertension can be increased when Diethylpropion is combined with Salmeterol.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be decreased when combined with Salmeterol.]
[C08CA03, isradipine, The metabolism of Salmeterol can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Salmeterol.]
[A03AB11, poldine, The risk or severity of Tachycardia can be increased when Salmeterol is combined with Poldine.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Diflunisal is combined with Salmeterol.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Digitoxin.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Salmeterol.]
[C02DB01, dihydralazine, Salmeterol may decrease the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, Dihydroergocristine may increase the hypertensive and vasoconstricting activities of Salmeterol.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Salmeterol.]
[J05AE08, atazanavir, The metabolism of Salmeterol can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The serum concentration of Treprostinil can be increased when it is combined with Salmeterol.]
[C08DB01, diltiazem, The metabolism of Diltiazem can be decreased when combined with Salmeterol.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Dimenhydrinate.]
[R06AB03, dimethindene, The risk or severity of Tachycardia can be increased when Salmeterol is combined with Dimetindene.]
[R03CC08, procaterol, The risk or severity of adverse effects can be increased when Salmeterol is combined with Procaterol.]
[N06BC02, propentofylline, The risk or severity of hypokalemia can be increased when Propentofylline is combined with Salmeterol.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Salmeterol is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Salmeterol is combined with Proglumetacin.]
[G02AD02, dinoprostone, The risk or severity of adverse effects can be increased when Dinoprostone is combined with Salmeterol.]
[R03DA03, proxyphylline, The risk or severity of hypokalemia can be increased when Proxyphylline is combined with Salmeterol.]
[R06AA02, diphenhydramine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Diphenhydramine.]
[C09AA06, quinapril, Salmeterol may decrease the antihypertensive activities of Quinapril.]
[N06BA11, dexmethylphenidate, The risk or severity of hypertension can be increased when Salmeterol is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of hypertension can be increased when Quinupramine is combined with Salmeterol.]
[A03FA02, cisapride, The metabolism of Cisapride can be decreased when combined with Salmeterol.]
[C09AA05, ramipril, Salmeterol may decrease the antihypertensive activities of Ramipril.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Salmeterol.]
[R03CC14, reproterol, The risk or severity of hypertension can be increased when Salmeterol is combined with Reproterol.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Salmeterol.]
[S02AA12, rifamycin SV, The metabolism of Salmeterol can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Salmeterol can be increased when combined with Rifapentine.]
[N05AX08, risperidone, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Levocetirizine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Salmeterol.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Salmeterol.]
[A04AD12, aprepitant, The metabolism of Salmeterol can be decreased when combined with Aprepitant.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Salmeterol.]
[G04BE08, tadalafil, Salmeterol may decrease the antihypertensive activities of Tadalafil.]
[S01BC05, ketorolac, The metabolism of Ketorolac can be decreased when combined with Salmeterol.]
[C02KX02, ambrisentan, Salmeterol may decrease the antihypertensive activities of Ambrisentan.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Salmeterol is combined with Salsalate.]
[S01AA13, fusidic acid, The metabolism of Salmeterol can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Pipemidic acid.]
[S02BA08, fluocinolone acetonide, The risk or severity of hypokalemia can be increased when Fluocinolone acetonide is combined with Salmeterol.]
[M01AG01, mefenamic acid, The risk or severity of hypertension can be increased when Mefenamic acid is combined with Salmeterol.]
[C01CA07, dobutamine, The risk or severity of adverse effects can be increased when Dobutamine is combined with Salmeterol.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Salmeterol.]
[C01CA04, dopamine, The serum concentration of Dopamine can be increased when it is combined with Salmeterol.]
[N06AA16, dothiepin, The risk or severity of hypertension can be increased when Dosulepin is combined with Salmeterol.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Salmeterol.]
[N06AA12, doxepin, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Doxepin.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Salmeterol.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Sevoflurane.]
[N05AD08, droperidol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Droperidol.]
[A08AA10, sibutramine, Sibutramine may increase the tachycardic activities of Salmeterol.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Salmeterol.]
[C09AA11, spirapril, Salmeterol may decrease the antihypertensive activities of Spirapril.]
[R03DA01, dyphylline, The risk or severity of hypokalemia can be increased when Dyphylline is combined with Salmeterol.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of hypertension can be increased when Sumatriptan is combined with Salmeterol.]
[C07AB13, talinolol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Talinolol.]
[H01AA01, corticotropin, The risk or severity of hypokalemia can be increased when Corticotropin is combined with Salmeterol.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Temafloxacin.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Tenoxicam is combined with Salmeterol.]
[G04CA03, terazosin, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Terazosin.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Salmeterol.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Terodiline.]
[C07AA16, tertatolol, Tertatolol may decrease the bronchodilatory activities of Salmeterol.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Salmeterol is combined with Tetryzoline.]
[G04BD01, emepronium, The risk or severity of Tachycardia can be increased when Salmeterol is combined with Emepronium.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Emetine.]
[N06AX14, tianeptine, The risk or severity of hypertension can be increased when Tianeptine is combined with Salmeterol.]
[C09AA02, enalapril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Salmeterol.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Salmeterol is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of hypertension can be increased when Salmeterol is combined with Toloxatone.]
[N06BA09, atomoxetine, Atomoxetine may increase the tachycardic activities of Salmeterol.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Toremifene.]
[C03CA04, torsemide, The risk or severity of hypokalemia can be increased when Salmeterol is combined with Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Salmeterol is combined with Tramazoline.]
[C09AA10, trandolapril, Salmeterol may decrease the antihypertensive activities of Trandolapril.]
[A03AB08, tridihexethyl, The risk or severity of Tachycardia can be increased when Tridihexethyl is combined with Salmeterol.]
[H02CA01, trilostane, The risk or severity of hypokalemia can be increased when Trilostane is combined with Salmeterol.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Triptorelin.]
[N04AA12, tropatepine, The risk or severity of Tachycardia can be increased when Salmeterol is combined with Tropatepine.]
[R03CC11, tulobuterol, The risk or severity of hypertension can be increased when Salmeterol is combined with Tulobuterol.]
[C02CA06, urapidil, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Urapidil.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Salmeterol.]
[S01FB02, ephedrine, The risk or severity of hypertension can be increased when Salmeterol is combined with Ephedrine.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Salmeterol.]
[N06AX16, venlafaxine, Venlafaxine may increase the tachycardic activities of Salmeterol.]
[C01CX07, xamoterol, The risk or severity of hypertension can be increased when Salmeterol is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of hypertension can be increased when Salmeterol is combined with Xylometazoline.]
[C08CA12, mepirodipine, The metabolism of Salmeterol can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The risk or severity of adverse effects can be increased when Epinephrine is combined with Salmeterol.]
[C09AA15, zofenopril, Salmeterol may decrease the antihypertensive activities of Zofenopril.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Salmeterol is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Salmeterol.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Salmeterol.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Salmeterol is combined with Guanfacine.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Iloprost.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Salmeterol.]
[G02AB03, ergonovine, Ergometrine may increase the hypertensive and vasoconstricting activities of Salmeterol.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Salmeterol.]
[N02CA02, ergotamine, The metabolism of Salmeterol can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The serum concentration of Salmeterol can be increased when it is combined with Erythromycin.]
[G03CA03, estradiol, The metabolism of Estradiol can be decreased when combined with Salmeterol.]
[R03AC12, salmeterol, The risk or severity of hypokalemia can be increased when Fluticasone furoate is combined with Salmeterol.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Salmeterol.]
[C01CA15, gepefrine, The risk or severity of hypertension can be increased when Salmeterol is combined with Gepefrine.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be decreased when combined with Salmeterol.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ibutilide.]
[N04AA05, profenamine, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Profenamine.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Salmeterol.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Meloxicam is combined with Salmeterol.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Salmeterol is combined with Etilefrine.]
[N01AX07, etomidate, The risk or severity of hypertension can be increased when Etomidate is combined with Salmeterol.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Salmeterol.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ajmaline.]
[L04AD02, tacrolimus, The metabolism of Tacrolimus can be decreased when combined with Salmeterol.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Salmeterol.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Fleroxacin.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Salmeterol.]
[R06AX12, terfenadine, The metabolism of Salmeterol can be decreased when combined with Terfenadine.]
[N06AB08, fluvoxamine, The metabolism of Salmeterol can be decreased when combined with Fluvoxamine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Encainide.]
[L02AE02, leuprolide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Salmeterol.]
[C10AA03, pravastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pravastatin is combined with Salmeterol.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Salmeterol.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Fendiline.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Fenoprofen is combined with Salmeterol.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Salmeterol is combined with Fenoterol.]
[N02AB03, fentanyl, The risk or severity of hypertension can be increased when Fentanyl is combined with Salmeterol.]
[R03CC02, albuterol, The risk or severity of adverse effects can be increased when Salmeterol is combined with Salbutamol.]
[L01BB06, clofarabine, The serum concentration of Clofarabine can be increased when it is combined with Salmeterol.]
[L04AA40, cladribine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Salmeterol.]
[G04BD02, flavoxate, The risk or severity of Tachycardia can be increased when Salmeterol is combined with Flavoxate.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Flecainide.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Salmeterol is combined with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Salmeterol can be decreased when combined with Fluconazole.]
[H02AA02, fludrocortisone, The risk or severity of hypokalemia can be increased when Fludrocortisone is combined with Salmeterol.]
[D07XB01, flumethasone, The risk or severity of hypokalemia can be increased when Flumethasone is combined with Salmeterol.]
[D07AC08, fluocinonide, The risk or severity of hypokalemia can be increased when Fluocinonide is combined with Salmeterol.]
[N06AA14, melitracen, The risk or severity of hypertension can be increased when Melitracen is combined with Salmeterol.]
[H02AB03, fluocortolone, The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Salmeterol.]
[V03AZ01, ethanol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ethanol is combined with Salmeterol.]
[S01CB05, fluorometholone, The risk or severity of hypokalemia can be increased when Fluorometholone is combined with Salmeterol.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Salmeterol.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Salmeterol.]
[N05AF01, flupenthixol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Flupentixol.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Flurbiprofen is combined with Salmeterol.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Fluspirilene.]
[L02BB01, flutamide, The metabolism of Salmeterol can be decreased when combined with Flutamide.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Salmeterol.]
[N06BX17, adrafinil, The risk or severity of hypertension can be increased when Salmeterol is combined with Adrafinil.]
[G01AX06, furazolidone, The risk or severity of hypertension can be increased when Furazolidone is combined with Salmeterol.]
[J05AE10, darunavir, Darunavir may increase the QTc-prolonging activities of Salmeterol.]
[C03CA01, furosemide, The risk or severity of hypokalemia can be increased when Salmeterol is combined with Furosemide.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Salmeterol.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Salmeterol.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Gallopamil.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Ganciclovir.]
[C10AB04, gemfibrozil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Degarelix.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Salmeterol.]
[N04BC06, cabergoline, Cabergoline may increase the hypertensive and vasoconstricting activities of Salmeterol.]
[C01CA21, cafedrine, The risk or severity of hypokalemia can be increased when Cafedrine is combined with Salmeterol.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of hypertension can be increased when Alfentanil is combined with Salmeterol.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Salmeterol.]
[A10BB01, glyburide, The metabolism of Glyburide can be decreased when combined with Salmeterol.]
[N05CM18, dexmedetomidine, The risk or severity of hypertension can be increased when Dexmedetomidine is combined with Salmeterol.]
[C05AE01, nitroglycerin, Salmeterol may decrease the antihypertensive activities of Nitroglycerin.]
[C01BD04, dofetilide, The serum concentration of Dofetilide can be increased when it is combined with Salmeterol.]
[C02CA04, doxazosin, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Doxazosin.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Salmeterol.]
[C07AB09, esmolol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Esmolol.]
[C09AA09, fosinopril, Salmeterol may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Salmeterol may decrease the antihypertensive activities of Guanethidine.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Goserelin.]
[P01BX01, halofantrine, The metabolism of Halofantrine can be decreased when combined with Salmeterol.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of hypertension can be increased when Salmeterol is combined with Halothane.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Histrelin.]
[N05AH04, quetiapine, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Quetiapine.]
[L01CE02, irinotecan, The metabolism of Salmeterol can be decreased when combined with Irinotecan.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Salmeterol.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Salmeterol.]
[R03CC05, hexoprenaline, The risk or severity of adverse effects can be increased when Salmeterol is combined with Hexoprenaline.]
[J05AG01, nevirapine, The risk or severity of adverse effects can be increased when Nevirapine is combined with Salmeterol.]
[C08CA10, nilvadipine, The metabolism of Salmeterol can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypertension can be increased when Salmeterol is combined with Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Oxatomide.]
[C09AA04, perindopril, Salmeterol may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Salmeterol may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of hypokalemia can be increased when Salmeterol is combined with Hydrochlorothiazide.]
[S02BA01, hydrocortisone, The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Salmeterol.]
[C03AA02, hydroflumethiazide, The risk or severity of hypokalemia can be increased when Salmeterol is combined with Hydroflumethiazide.]
[G04BD06, propiverine, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Propiverine.]
[P01BA02, hydroxychloroquine, The metabolism of Hydroxychloroquine can be decreased when combined with Salmeterol.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Hydroxyzine.]
[C02AC06, rilmenidine, Salmeterol may decrease the antihypertensive activities of Rilmenidine.]
[M05BA07, risedronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Salmeterol.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Salmeterol.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Salmeterol.]
[N01AH03, sufentanil, The risk or severity of hypertension can be increased when Sufentanil is combined with Salmeterol.]
[N06AA02, imipramine, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Imipramine.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Salmeterol.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Terlipressin.]
[R01AD07, tixocortol, The risk or severity of hypokalemia can be increased when Tixocortol is combined with Salmeterol.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Salmeterol.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Salmeterol.]
[S01BC01, indomethacin, The risk or severity of hypertension can be increased when Indomethacin is combined with Salmeterol.]
[C02CA02, indoramin, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Indoramin.]
[N06AX17, milnacipran, Milnacipran may increase the tachycardic activities of Salmeterol.]
[A03AA30, piperidolate, The risk or severity of Tachycardia can be increased when Salmeterol is combined with Piperidolate.]
[S01XA28, varenicline, The excretion of Varenicline can be decreased when combined with Salmeterol.]
[A10BH01, sitagliptin, The metabolism of Sitagliptin can be decreased when combined with Salmeterol.]
[N05BA12, alprazolam, The metabolism of Salmeterol can be decreased when combined with Alprazolam.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Salmeterol.]
[G02CX01, atosiban, The risk or severity of adverse effects can be increased when Salmeterol is combined with Atosiban.]
[C10AA06, cerivastatin, The metabolism of Cerivastatin can be decreased when combined with Salmeterol.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Anagrelide.]
[C07AA01, alprenolol, Alprenolol may decrease the bronchodilatory activities of Salmeterol.]
[C03BA02, quinethazone, Salmeterol may increase the hypokalemic activities of Quinethazone.]
[V03AB01, ipecac, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Ipecac.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Salmeterol.]
[N06AA13, iprindole, The risk or severity of hypertension can be increased when Iprindole is combined with Salmeterol.]
[N06AF05, iproniazid, The risk or severity of hypertension can be increased when Salmeterol is combined with Iproniazid.]
[N06AF01, isocarboxazid, The risk or severity of hypertension can be increased when Salmeterol is combined with Isocarboxazid.]
[R03CC06, isoetharine, The risk or severity of adverse effects can be increased when Isoetharine is combined with Salmeterol.]
[C09AA16, imidapril, Salmeterol may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Salmeterol.]
[J04AC01, isoniazid, The metabolism of Salmeterol can be decreased when combined with Isoniazid.]
[R03CB01, isoproterenol, The risk or severity of adverse effects can be increased when Salmeterol is combined with Isoprenaline.]
[D10BA01, isotretinoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Isotretinoin.]
[C04AA01, isoxsuprine, The risk or severity of hypertension can be increased when Salmeterol is combined with Isoxsuprine.]
[P02CF01, ivermectin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Salmeterol.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Salmeterol.]
[L04AC07, tocilizumab, The metabolism of Salmeterol can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Ketamine can be decreased when combined with Salmeterol.]
[C02KD01, ketanserin, Salmeterol may decrease the antihypertensive activities of Ketanserin.]
[J02AB02, ketoconazole, The metabolism of Salmeterol can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Salmeterol is combined with Ketoprofen.]
[L04AA24, abatacept, The metabolism of Salmeterol can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Mizolastine.]
[C01CA22, arbutamine, The risk or severity of adverse effects can be increased when Salmeterol is combined with Arbutamine.]
[N04BC09, rotigotine, The risk or severity of hypertension can be increased when Salmeterol is combined with Rotigotine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Nalidixic acid.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Salmeterol is combined with Tiaprofenic acid.]
[C07AG01, labetalol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Labetalol.]
[N04BB01, amantadine, The serum concentration of Amantadine can be increased when it is combined with Salmeterol.]
[C02AA05, deserpidine, Salmeterol may decrease the antihypertensive activities of Deserpidine.]
[C03CC01, ethacrynic acid, The risk or severity of hypokalemia can be increased when Salmeterol is combined with Etacrynic acid.]
[G03AD01, levonorgestrel, The metabolism of Salmeterol can be decreased when combined with Levonorgestrel.]
[S02DA01, lidocaine, The metabolism of Salmeterol can be decreased when combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Lidoflazine.]
[N06BA13, armodafinil, The metabolism of Salmeterol can be increased when combined with Armodafinil.]
[N02CA07, lisuride, Lisuride may increase the hypertensive and vasoconstricting activities of Salmeterol.]
[N06AA07, lofepramine, The risk or severity of hypertension can be increased when Lofepramine is combined with Salmeterol.]
[A07DA03, loperamide, The metabolism of Loperamide can be decreased when combined with Salmeterol.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Salmeterol.]
[N05AH01, loxapine, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Loxapine.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Salmeterol.]
[L01EA03, nilotinib, The metabolism of Salmeterol can be decreased when combined with Nilotinib.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Salmeterol.]
[C02BB01, mecamylamine, Salmeterol may decrease the antihypertensive activities of Mecamylamine.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Salmeterol is combined with Meclofenamic acid.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Salmeterol.]
[N06DX01, memantine, The serum concentration of Memantine can be increased when it is combined with Salmeterol.]
[C01CA11, mephentermine, The risk or severity of hypertension can be increased when Salmeterol is combined with Mephentermine.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Salmeterol.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Mesoridazine.]
[N05AX13, paliperidone, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Paliperidone.]
[C01CA09, metaraminol, The risk or severity of hypertension can be increased when Metaraminol is combined with Salmeterol.]
[A10BA02, metformin, The serum concentration of Metformin can be increased when it is combined with Salmeterol.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Dolasetron.]
[N07BC02, methadone, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Methadone.]
[N06BA03, methamphetamine, The risk or severity of hypertension can be increased when Salmeterol is combined with Metamfetamine.]
[A03AB07, methantheline, The risk or severity of Tachycardia can be increased when Salmeterol is combined with Methantheline.]
[J05AF05, lamivudine, The serum concentration of Lamivudine can be increased when it is combined with Salmeterol.]
[G02CB05, metergoline, Metergoline may increase the hypertensive and vasoconstricting activities of Salmeterol.]
[H03BB02, methimazole, The metabolism of Salmeterol can be decreased when combined with Methimazole.]
[L04AX03, methotrexate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methotrexate is combined with Salmeterol.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of hypertension can be increased when Methoxamine is combined with Salmeterol.]
[N02BG09, methoxyflurane, The risk or severity of hypertension can be increased when Salmeterol is combined with Methoxyflurane.]
[C03AA08, methyclothiazide, The risk or severity of hypokalemia can be increased when Salmeterol is combined with Methyclothiazide.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Methyldopa.]
[V04CG05, methylene blue, The metabolism of Salmeterol can be decreased when combined with Methylene blue.]
[G02AB01, methylergonovine, Methylergometrine may increase the hypertensive and vasoconstricting activities of Salmeterol.]
[R03DA05, aminophylline, The risk or severity of hypokalemia can be increased when Aminophylline is combined with Salmeterol.]
[N06BA04, methylphenidate, The risk or severity of hypertension can be increased when Methylphenidate is combined with Salmeterol.]
[H02AB04, methylprednisolone, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Salmeterol.]
[D07AC14, methylprednisolone aceponate, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Salmeterol.]
[N02CA04, methysergide, Methysergide may increase the hypertensive and vasoconstricting activities of Salmeterol.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Metoclopramide.]
[C03BA08, metolazone, Salmeterol may decrease the antihypertensive activities of Metolazone.]
[C07AB02, metoprolol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Salmeterol.]
[N06AX03, mianserin, The risk or severity of hypertension can be increased when Salmeterol is combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Salmeterol can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Salmeterol.]
[N05CD08, midazolam, The metabolism of Salmeterol can be decreased when combined with Midazolam.]
[C01CA17, midodrine, The risk or severity of hypertension can be increased when Midodrine is combined with Salmeterol.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Mifepristone.]
[C09CA03, valsartan, Salmeterol may decrease the antihypertensive activities of Valsartan.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Minocycline.]
[D11AX01, minoxidil, Salmeterol may decrease the antihypertensive activities of Minoxidil.]
[L01XX23, mitotane, The metabolism of Salmeterol can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The risk or severity of hypertension can be increased when Salmeterol is combined with Lisdexamfetamine.]
[C01BD01, amiodarone, The metabolism of Salmeterol can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Salmeterol.]
[N02AA01, morphine, The metabolism of Morphine can be decreased when combined with Salmeterol.]
[L04AB05, certolizumab pegol, The metabolism of Salmeterol can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Salmeterol.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Salmeterol.]
[J05AJ01, raltegravir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Raltegravir.]
[P01BA06, amodiaquine, The metabolism of Amodiaquine can be decreased when combined with Salmeterol.]
[G04CA04, silodosin, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Silodosin.]
[N06AA17, amoxapine, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Amoxapine.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be decreased when combined with Salmeterol.]
[C07AA12, nadolol, Nadolol may decrease the bronchodilatory activities of Salmeterol.]
[V03AB15, naloxone, The metabolism of Salmeterol can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Salmeterol.]
[L04AC03, anakinra, The metabolism of Salmeterol can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The risk or severity of hypertension can be increased when Salmeterol is combined with Naphazoline.]
[N06BA01, amphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Salmeterol.]
[M02AA12, naproxen, The metabolism of Naproxen can be decreased when combined with Salmeterol.]
[A10BG01, troglitazone, The metabolism of Troglitazone can be decreased when combined with Salmeterol.]
[N06AX21, duloxetine, Duloxetine may increase the tachycardic activities of Salmeterol.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Salmeterol.]
[L02BG04, letrozole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Letrozole.]
[N01AH06, remifentanil, The risk or severity of hypertension can be increased when Remifentanil is combined with Salmeterol.]
[A10BX02, repaglinide, The metabolism of Repaglinide can be decreased when combined with Salmeterol.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Levosimendan.]
[N05AX14, iloperidone, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Salmeterol.]
[N06AX23, desvenlafaxine, Desvenlafaxine may increase the tachycardic activities of Salmeterol.]
[C09CA07, telmisartan, Salmeterol may decrease the antihypertensive activities of Telmisartan.]
[C10AD02, niacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Salmeterol.]
[N06AF02, nialamide, The risk or severity of hypertension can be increased when Salmeterol is combined with Nialamide.]
[C08CA04, nicardipine, The metabolism of Nicardipine can be decreased when combined with Salmeterol.]
[C04AE02, nicergoline, Nicergoline may increase the hypertensive and vasoconstricting activities of Salmeterol.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Nicotine is combined with Salmeterol.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Nifedipine.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Salmeterol is combined with Niflumic acid.]
[C08CA06, nimodipine, Salmeterol may decrease the antihypertensive activities of Nimodipine.]
[C08CA07, nisoldipine, Salmeterol may decrease the antihypertensive activities of Nisoldipine.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Nitrendipine.]
[N05CF03, zaleplon, The metabolism of Zaleplon can be decreased when combined with Salmeterol.]
[N04BC05, pramipexole, The serum concentration of Pramipexole can be increased when it is combined with Salmeterol.]
[C02DD01, nitroprusside, Salmeterol may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of hypertension can be increased when Salmeterol is combined with Nitrous oxide.]
[C01CA03, norepinephrine, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Salmeterol.]
[G03DC02, norethindrone, The metabolism of Salmeterol can be decreased when combined with Norethisterone.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Norfloxacin.]
[C02KX01, bosentan, Salmeterol may decrease the antihypertensive activities of Bosentan.]
[N06AA10, nortriptyline, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Nortriptyline.]
[G02CA02, nylidrin, The risk or severity of hypertension can be increased when Salmeterol is combined with Nylidrin.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Salmeterol.]
[S02AA16, ofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Ofloxacin.]
[L04AC04, rilonacept, The metabolism of Salmeterol can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Salmeterol.]
[N06AA05, opipramol, The risk or severity of hypertension can be increased when Opipramol is combined with Salmeterol.]
[R03CB03, metaproterenol, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Salmeterol.]
[G04CA02, tamsulosin, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Tamsulosin.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Oxolinic acid.]
[C07AA02, oxprenolol, Oxprenolol may decrease the bronchodilatory activities of Salmeterol.]
[N02AA05, oxycodone, The metabolism of Salmeterol can be decreased when combined with Oxycodone.]
[C01DX03, oxyfedrine, The risk or severity of hypertension can be increased when Salmeterol is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of hypertension can be increased when Oxymetazoline is combined with Salmeterol.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Salmeterol is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, The risk or severity of Tachycardia can be increased when Oxyphenonium is combined with Salmeterol.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Salmeterol.]
[N05AH05, asenapine, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Asenapine.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Salmeterol is combined with Pancuronium.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Papaverine.]
[H02AB05, paramethasone, The risk or severity of hypokalemia can be increased when Paramethasone is combined with Salmeterol.]
[C02KC01, pargyline, Salmeterol may decrease the antihypertensive activities of Pargyline.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Salmeterol.]
[G04BD11, fesoterodine, The risk or severity of Tachycardia can be increased when Salmeterol is combined with Fesoterodine.]
[C07AA23, penbutolol, Penbutolol may decrease the bronchodilatory activities of Salmeterol.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Penfluridol.]
[M01CC01, penicillamine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Penicillamine is combined with Salmeterol.]
[N05CA01, pentobarbital, The metabolism of Salmeterol can be increased when combined with Pentobarbital.]
[C04AD03, pentoxifylline, The risk or severity of hypokalemia can be increased when Pentoxifylline is combined with Salmeterol.]
[N04BC02, pergolide, Pergolide may increase the hypertensive and vasoconstricting activities of Salmeterol.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Perhexiline.]
[N06AF03, phenelzine, The risk or severity of hypertension can be increased when Phenelzine is combined with Salmeterol.]
[A10BA01, phenformin, The risk or severity of adverse effects can be increased when Phenformin is combined with Salmeterol.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Pheniramine.]
[N03AA02, phenobarbital, The metabolism of Salmeterol can be increased when combined with Phenobarbital.]
[C04AX02, phenoxybenzamine, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Phenoxybenzamine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Salmeterol.]
[A08AA01, phentermine, The risk or severity of hypertension can be increased when Phentermine is combined with Salmeterol.]
[V03AB36, phentolamine, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Phentolamine.]
[M02AA01, phenylbutazone, The risk or severity of hypertension can be increased when Phenylbutazone is combined with Salmeterol.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Phenylephrine is combined with Salmeterol.]
[R01BA01, phenylpropanolamine, The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Salmeterol.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be decreased when combined with Salmeterol.]
[L04AB06, golimumab, The metabolism of Salmeterol can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Levofloxacin.]
[C08CX01, mibefradil, The metabolism of Salmeterol can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Salmeterol.]
[C07AA03, pindolol, Pindolol may decrease the bronchodilatory activities of Salmeterol.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Salmeterol.]
[J05AE01, saquinavir, The metabolism of Salmeterol can be decreased when combined with Saquinavir.]
[C09CA02, eprosartan, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Eprosartan is combined with Salmeterol.]
[A02BX03, pirenzepine, The risk or severity of Tachycardia can be increased when Pirenzepine is combined with Salmeterol.]
[S01BC06, piroxicam, The metabolism of Piroxicam can be decreased when combined with Salmeterol.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Grepafloxacin.]
[N02CX01, pizotyline, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Pizotifen.]
[J05AG02, delavirdine, The metabolism of Salmeterol can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be decreased when combined with Salmeterol.]
[D05AX05, tazarotene, The metabolism of Tazarotene can be decreased when combined with Salmeterol.]
[A10BG02, rosiglitazone, The metabolism of Rosiglitazone can be decreased when combined with Salmeterol.]
[L02BG03, anastrozole, The metabolism of Anastrozole can be decreased when combined with Salmeterol.]
[L04AC08, canakinumab, The metabolism of Salmeterol can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of hypokalemia can be increased when Salmeterol is combined with Polythiazide.]
[J05AE03, ritonavir, The metabolism of Salmeterol can be decreased when combined with Ritonavir.]
[A10BH03, saxagliptin, The metabolism of Saxagliptin can be decreased when combined with Salmeterol.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Salmeterol.]
[C07AB01, practolol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Practolol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Prajmaline.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Salmeterol.]
[C02CA01, prazosin, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Prazosin.]
[S03BA02, prednisolone, The risk or severity of hypokalemia can be increased when Prednisolone is combined with Salmeterol.]
[H02AB07, prednisone, The risk or severity of hypokalemia can be increased when Prednisone is combined with Salmeterol.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Prenylamine.]
[P01BA03, primaquine, The metabolism of Salmeterol can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Salmeterol can be increased when combined with Primidone.]
[M04AB01, probenecid, The risk or severity of adverse effects can be increased when Probenecid is combined with Salmeterol.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Probucol.]
[C01BA02, procainamide, The serum concentration of Procainamide can be increased when it is combined with Salmeterol.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Procaine is combined with Salmeterol.]
[L01XB01, procarbazine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Procarbazine.]
[C10AB05, fenofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Fenofibrate.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Prochlorperazine.]
[N04AA04, procyclidine, The risk or severity of Tachycardia can be increased when Procyclidine is combined with Salmeterol.]
[G03DA04, progesterone, The metabolism of Salmeterol can be decreased when combined with Progesterone.]
[N05AA03, promazine, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Promazine.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Promethazine.]
[C01BC03, propafenone, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Propafenone.]
[A03AB05, propantheline, The risk or severity of Tachycardia can be increased when Propantheline is combined with Salmeterol.]
[N05AC01, periciazine, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Periciazine.]
[N05CM06, propiomazine, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Propiomazine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Romidepsin.]
[N01AX10, propofol, The metabolism of Propofol can be decreased when combined with Salmeterol.]
[C07AA05, propranolol, Propranolol may decrease the bronchodilatory activities of Salmeterol.]
[H03BA02, propylthiouracil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Salmeterol.]
[N02CC04, rizatriptan, The risk or severity of hypertension can be increased when Salmeterol is combined with Rizatriptan.]
[B01AC09, epoprostenol, Salmeterol may decrease the antihypertensive activities of Epoprostenol.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Salmeterol.]
[N06AA11, protriptyline, The risk or severity of hypertension can be increased when Protriptyline is combined with Salmeterol.]
[R01BA02, pseudoephedrine, The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Salmeterol.]
[N05AX12, aripiprazole, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Aripiprazole.]
[N07XX07, dalfampridine, The serum concentration of Dalfampridine can be increased when it is combined with Salmeterol.]
[A03AB15, diphemanil, The risk or severity of Tachycardia can be increased when Salmeterol is combined with Diphemanil.]
[A03AB09, isopropamide, The risk or severity of Tachycardia can be increased when Salmeterol is combined with Isopropamide.]
[S01FA03, methscopolamine, The risk or severity of Tachycardia can be increased when Salmeterol is combined with Methscopolamine.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Mepyramine.]
[P01AX05, quinacrine, The metabolism of Quinacrine can be decreased when combined with Salmeterol.]
[C01BA01, quinidine, The metabolism of Quinidine can be decreased when combined with Salmeterol.]
[P01BC01, quinine, The metabolism of Quinine can be decreased when combined with Salmeterol.]
[A02BA02, ranitidine, The serum concentration of Ranitidine can be increased when it is combined with Salmeterol.]
[C02AA01, rescinnamine, Salmeterol may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, The serum concentration of Reserpine can be increased when it is combined with Salmeterol.]
[J04AB02, rifampin, The metabolism of Salmeterol can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The risk or severity of hypertension can be increased when Salmeterol is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of adverse effects can be increased when Ritodrine is combined with Salmeterol.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Roxithromycin.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Salmeterol is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Sulfasalazine is combined with Salmeterol.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Salicylic acid is combined with Salmeterol.]
[S01FA02, scopolamine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Salmeterol.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Salmeterol.]
[C07AA07, sotalol, Sotalol may decrease the bronchodilatory activities of Salmeterol.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Salmeterol.]
[C03DA01, spironolactone, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Spironolactone.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Valproic acid.]
[M05BA04, alendronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Salmeterol.]
[D07AB02, hydrocortisone butyrate, The risk or severity of hypokalemia can be increased when Hydrocortisone butyrate is combined with Salmeterol.]
[H02CA04, levoketoconazole, The metabolism of Salmeterol can be decreased when combined with Levoketoconazole.]
[R03BB01, ipratropium bromide, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Salmeterol.]
[P02BB01, trichlorfon, The therapeutic efficacy of Metrifonate can be decreased when used in combination with Fluticasone.]
[S02DA03, antipyrine, The risk or severity of gastrointestinal irritation can be increased when Fluticasone is combined with Antipyrine.]
[A14AA02, stanozolol, The risk or severity of fluid retention can be increased when Fluticasone is combined with Stanozolol.]
[G03XB02, ulipristal, The serum concentration of Fluticasone can be increased when it is combined with Ulipristal.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluticasone.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Fluticasone.]
[L04AA27, fingolimod, Fluticasone may increase the immunosuppressive activities of Fingolimod.]
[M03AB01, succinylcholine, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fluticasone.]
[J01EC02, sulfadiazine, The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Sulfadiazine.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Fluticasone.]
[S01AB02, sulfisoxazole, The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of gastrointestinal irritation can be increased when Fluticasone is combined with Sulindac.]
[N05AL01, sulpiride, The therapeutic efficacy of Sulpiride can be decreased when used in combination with Fluticasone.]
[A10BB04, glibornuride, The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Glibornuride.]
[A10BC01, glymidine, The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Glymidine.]
[M01AX04, apazone, The risk or severity of gastrointestinal irritation can be increased when Fluticasone is combined with Azapropazone.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Fluticasone.]
[N06DA01, tacrine, The therapeutic efficacy of Tacrine can be decreased when used in combination with Fluticasone.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be increased when combined with Fluticasone.]
[L01CB02, teniposide, The metabolism of Teniposide can be increased when combined with Fluticasone.]
[R03CC03, terbutaline, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Fluticasone.]
[G03BA03, testosterone, The risk or severity of edema formation can be increased when Testosterone is combined with Fluticasone.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Fluticasone.]
[N04BC07, apomorphine, The metabolism of Apomorphine can be decreased when combined with Fluticasone.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Fluticasone.]
[R03DA04, theophylline, The metabolism of Theophylline can be increased when combined with Fluticasone.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Eribulin is combined with Fluticasone.]
[L01AC01, thiotepa, The therapeutic efficacy of Thiotepa can be decreased when used in combination with Fluticasone.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Fluticasone.]
[B02AB01, aprotinin, The therapeutic efficacy of Aprotinin can be decreased when used in combination with Fluticasone.]
[A10BB05, tolazamide, The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Tolazamide.]
[V04CA01, tolbutamide, The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Tolbutamide.]
[M02AA21, tolmetin, The risk or severity of gastrointestinal irritation can be increased when Fluticasone is combined with Tolmetin.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Fluticasone.]
[N06AX05, trazodone, The metabolism of Trazodone can be decreased when combined with Fluticasone.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Fluticasone.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Triamcinolone is combined with Fluticasone.]
[N05CD05, triazolam, The metabolism of Triazolam can be decreased when combined with Fluticasone.]
[C03AA06, trichlormethiazide, The risk or severity of electrolyte imbalance can be increased when Fluticasone is combined with Trichlormethiazide.]
[S01EB04, demecarium, The therapeutic efficacy of Demecarium can be decreased when used in combination with Fluticasone.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Fluticasone.]
[N05AA05, triflupromazine, The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Fluticasone.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Fluclorolone is combined with Fluticasone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Mometasone is combined with Fluticasone.]
[N03AC02, trimethadione, The metabolism of Trimethadione can be decreased when combined with Fluticasone.]
[J01FA08, troleandomycin, The metabolism of Fluticasone can be decreased when combined with Troleandomycin.]
[M03AA02, tubocurarine, The therapeutic efficacy of Tubocurarine can be decreased when used in combination with Fluticasone.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Fluticasone.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Belimumab is combined with Fluticasone.]
[S01AA05, tyrothricin, The therapeutic efficacy of Tyrothricin can be decreased when used in combination with Fluticasone.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be increased when combined with Fluticasone.]
[A10BH05, linagliptin, The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Fluticasone can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Telaprevir can be decreased when combined with Fluticasone.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Fluticasone.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Belatacept is combined with Fluticasone.]
[B01AF01, rivaroxaban, The metabolism of Rivaroxaban can be decreased when combined with Fluticasone.]
[R03AC18, indacaterol, The risk or severity of hypokalemia can be increased when Fluticasone is combined with Indacaterol.]
[B01AC24, ticagrelor, The metabolism of Ticagrelor can be decreased when combined with Fluticasone.]
[C08DA01, verapamil, The metabolism of Verapamil can be decreased when combined with Fluticasone.]
[N06AX09, viloxazine, The metabolism of Fluticasone can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be increased when combined with Fluticasone.]
[L01CA02, vincristine, The metabolism of Vincristine can be increased when combined with Fluticasone.]
[L01CA03, vindesine, The metabolism of Vindesine can be increased when combined with Fluticasone.]
[B01AA03, warfarin, Fluticasone may increase the anticoagulant activities of Warfarin.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Fluticasone.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be increased when combined with Fluticasone.]
[J05AE02, indinavir, The metabolism of Indinavir can be decreased when combined with Fluticasone.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be increased when combined with Fluticasone.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be increased when combined with Fluticasone.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be increased when combined with Fluticasone.]
[H05BX03, doxercalciferol, The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Fluticasone.]
[J01MA13, trovafloxacin, The risk or severity of tendinopathy can be increased when Fluticasone is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The metabolism of Ziprasidone can be increased when combined with Fluticasone.]
[G03AC10, drospirenone, The serum concentration of Fluticasone can be increased when it is combined with Drospirenone.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluticasone.]
[N02BA01, aspirin, The risk or severity of adverse effects can be increased when Fluticasone is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be increased when combined with Fluticasone.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluticasone.]
[A11CC03, alfacalcidol, The therapeutic efficacy of Alfacalcidol can be decreased when used in combination with Fluticasone.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Fluticasone.]
[J02AC03, voriconazole, The serum concentration of Fluticasone can be increased when it is combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of myopathy and weakness can be increased when Atracurium is combined with Fluticasone.]
[L01EK01, axitinib, The metabolism of Axitinib can be increased when combined with Fluticasone.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be decreased when combined with Fluticasone.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Prednylidene is combined with Fluticasone.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Fluticasone.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Fluticasone.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Fluticasone.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Fluticasone.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Fluticasone.]
